Get access

Gefitinib for advanced non-small cell lung cancer

  • Protocol
  • Intervention

Authors


Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the efficacy and safety of gefitinib as first or second line treatment of advanced non-small cell lung cancer (NSCLC) by undertaking the following comparisons:
a) Gefitinib at any dose compared with placebo or best supportive care for NSCLC
b) Gefitinib at any dose compared with other chemotherapeutic agents
c) Gefitinib at any dose in combination with other chemotherapeutic agents versus the same chemotherapy agents alone
d) Gefitinib at any dose in combination with other chemotherapeutic agents versus a different combination of chemotherapeutic agents
e) Gefitinib versus gefitinib combined with a chemotherapy regimen

Get access to the full text of this article